|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 5 (March 1), 2000:
pp. 1588-1593
Predictors of therapy-related leukemia and myelodysplasia
following autologous transplantation for lymphoma: an assessment of
risk factors
Amrita Krishnan,
Smita Bhatia,
Marilyn L. Slovak,
Daniel A. Arber,
Joyce C. Niland,
Auayporn Nademanee,
Henry Fung,
Ravi Bhatia,
Ashwin Kashyap,
Arturo Molina,
Margaret R. O'Donnell,
Pablo A. Parker,
Irena Sniecinski,
David S. Snyder,
Ricardo Spielberger,
Anthony Stein, and
Stephen J. Forman
Divisions of Hematology and Bone Marrow Transplantation,
Pediatric Oncology, Biostatistics and Pathology, City of Hope
National Medical Center, Duarte, CA.
We analyzed data on 612 patients who had undergone high-dose
chemoradiotherapy (HDT) with autologous stem cell rescue for Hodgkin's
disease (HD) and non-Hodgkin's lymphoma (NHL) at the City of Hope
National Medical Center, to evaluate the incidence of therapy-related
myelodysplasia (t-MDS) or therapy-related acute myeloid leukemia
(t-AML) and associated risk factors. A retrospective cohort and a
nested case-control study design were used to evaluate the role of
pretransplant therapeutic exposures and transplant conditioning
regimens. Twenty-two patients developed morphologic evidence of
t-MDS/t-AML. The estimated cumulative probability of developing
morphologic t-MDS/t-AML was 8.6% ± 2.1% at 6 years. Multivariate
analysis of the entire cohort revealed stem cell priming with VP-16
(RR = 7.7, P = 0.002) to be independently associated with an increased risk of t-MDS/t-AML. The influence of pretransplant therapy on subsequent t-MDS/t-AML risk was determined by a case-control study. Multivariate analysis revealed an association between
pretransplant radiation and the risk of t-MDS/t-AML, but failed to
reveal any association with pretransplant chemotherapy or conditioning
regimens. However, patients who had been primed with VP-16 for stem
cell mobilization were at a 12.3-fold increased risk of developing t-AML with 11q23/21q22 abnormalities (P = 0.006). Patients
undergoing HDT with stem cell rescue are at an increased risk of
t-MDS/t-AML, especially those receiving priming with VP-16 for
peripheral stem cell collection.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C. Gisselbrecht, J. Vose, A. Nademanee, A. M. Gianni, and A. Nagler
Radioimmunotherapy for Stem Cell Transplantation in Non-Hodgkin's Lymphoma: In Pursuit of a Complete Response
Oncologist,
October 1, 2009;
14(suppl_2):
41 - 51.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. N. Winter, D. J. Inwards, S. Spies, G. Wiseman, D. Patton, W. Erwin, A. W. Rademaker, B. B. Weitner, S. F. Williams, M. S. Tallman, et al.
Yttrium-90 Ibritumomab Tiuxetan Doses Calculated to Deliver up to 15 Gy to Critical Organs May Be Safely Combined With High-Dose BEAM and Autologous Transplantation in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
April 1, 2009;
27(10):
1653 - 1659.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chakraborty, C.-L. Sun, L. Francisco, M. Sabado, L. Li, K. L. Chang, S. Forman, S. Bhatia, and R. Bhatia
Accelerated Telomere Shortening Precedes Development of Therapy-Related Myelodysplasia or Acute Myelogenous Leukemia After Autologous Transplantation for Lymphoma
J. Clin. Oncol.,
February 10, 2009;
27(5):
791 - 798.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Barlogie, G. Tricot, J. Haessler, F. van Rhee, M. Cottler-Fox, E. Anaissie, J. Waldron, M. Pineda-Roman, R. Thertulien, M. Zangari, et al.
Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3000 patients treated since 1989
Blood,
January 1, 2008;
111(1):
94 - 100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bhatia, L. Francisco, A. Carter, C.-L. Sun, K. S. Baker, J. G. Gurney, P. B. McGlave, A. Nademanee, M. O'Donnell, N. K. C. Ramsay, et al.
Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study
Blood,
November 15, 2007;
110(10):
3784 - 3792.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. Gopal, J. G. Rajendran, T. A. Gooley, J. M. Pagel, D. R. Fisher, S. H. Petersdorf, D. G. Maloney, J. F. Eary, F. R. Appelbaum, and O. W. Press
High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem-Cell Transplantation for Adults >= 60 Years Old With Relapsed or Refractory B-Cell Lymphoma
J. Clin. Oncol.,
April 10, 2007;
25(11):
1396 - 1402.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Sebban, N. Mounier, N. Brousse, C. Belanger, P. Brice, C. Haioun, H. Tilly, P. Feugier, R. Bouabdallah, C. Doyen, et al.
Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Blood,
October 15, 2006;
108(8):
2540 - 2544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Kalaycio, L. Rybicki, B. Pohlman, R. Sobecks, S. Andresen, E. Kuczkowski, and B. Bolwell
Risk Factors Before Autologous Stem-Cell Transplantation for Lymphoma Predict for Secondary Myelodysplasia and Acute Myelogenous Leukemia
J. Clin. Oncol.,
August 1, 2006;
24(22):
3604 - 3610.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Copelan
Hematopoietic stem-cell transplantation.
N. Engl. J. Med.,
April 27, 2006;
354(17):
1813 - 1826.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Forrest, D. E. Hogge, T. J. Nevill, S. H. Nantel, M. J. Barnett, J. D. Shepherd, H. J. Sutherland, C. L. Toze, C. A. Smith, J. C. Lavoie, et al.
High-Dose Therapy and Autologous Hematopoietic Stem-Cell Transplantation Does Not Increase the Risk of Second Neoplasms for Patients With Hodgkin's Lymphoma: A Comparison of Conventional Therapy Alone Versus Conventional Therapy Followed by Autologous Hematopoietic Stem-Cell Transplantation
J. Clin. Oncol.,
November 1, 2005;
23(31):
7994 - 8002.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bhatia, K. Van Heijzen, A. Palmer, A. Komiya, M. L. Slovak, K. L. Chang, H. Fung, A. Krishnan, A. Molina, A. Nademanee, et al.
Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma
J. Clin. Oncol.,
September 20, 2005;
23(27):
6699 - 6711.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bhatia, L. L. Robison, L. Francisco, A. Carter, Y. Liu, M. Grant, K. S. Baker, H. Fung, J. G. Gurney, P. B. McGlave, et al.
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study
Blood,
June 1, 2005;
105(11):
4215 - 4222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Brown, H. Yeckes, J. W. Friedberg, D. Neuberg, H. Kim, L. M. Nadler, and A. S. Freedman
Increasing Incidence of Late Second Malignancies After Conditioning With Cyclophosphamide and Total-Body Irradiation and Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
April 1, 2005;
23(10):
2208 - 2214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Lenz, M. Dreyling, E. Schiegnitz, T. Haferlach, J. Hasford, M. Unterhalt, and W. Hiddemann
Moderate Increase of Secondary Hematologic Malignancies After Myeloablative Radiochemotherapy and Autologous Stem-Cell Transplantation in Patients With Indolent Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group
J. Clin. Oncol.,
December 15, 2004;
22(24):
4926 - 4933.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Czyz, R. Dziadziuszko, W. Knopinska-Postuszuy, A. Hellmann, L. Kachel, J. Holowiecki, J. Gozdzik, J. Hansz, A. Avigdor, A. Nagler, et al.
Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: a study of 341 patients
Ann. Onc.,
August 1, 2004;
15(8):
1222 - 1230.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Smith, M. M. Le Beau, D. Huo, T. Karrison, R. M. Sobecks, J. Anastasi, J. W. Vardiman, J. D. Rowley, and R. A. Larson
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
Blood,
July 1, 2003;
102(1):
43 - 52.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O. Armitage, P. P. Carbone, J. M. Connors, A. Levine, J. M. Bennett, and S. Kroll
Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients
J. Clin. Oncol.,
March 1, 2003;
21(5):
897 - 906.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Metayer, R. E. Curtis, J. Vose, K. A. Sobocinski, M. M. Horowitz, S. Bhatia, J. W. Fay, C. O. Freytes, S. C. Goldstein, R. H. Herzig, et al.
Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study
Blood,
March 1, 2003;
101(5):
2015 - 2023.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Diehl
Advanced Hodgkin's Disease: ABVD Is Better, Yet Is Not Good Enough!
J. Clin. Oncol.,
February 15, 2003;
21(4):
583 - 585.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hunault-Berger, N. Ifrah, and P. Solal-Celigny
Intensive therapies in follicular non-Hodgkin lymphomas
Blood,
July 30, 2002;
100(4):
1141 - 1152.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Montoto, A. Lopez-Guillermo, A. Ferrer, M. Camos, A. Alvarez-Larran, F. Bosch, J. Blade, F. Cervantes, J. Esteve, F. Cobo, et al.
Survival after progression in patients with follicular lymphoma: analysis of prognostic factors
Ann. Onc.,
April 1, 2002;
13(4):
523 - 530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Hosing, M. Munsell, S. Yazji, B. Andersson, D. Couriel, M. de Lima, M. Donato, J. Gajewski, S. Giralt, M. Korbling, et al.
Risk of therapy-related myelodysplastic syndrome/acute leukemia following high-dose therapy and autologous bone marrow transplantation for non-Hodgkin's lymphoma
Ann. Onc.,
March 1, 2002;
13(3):
450 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. C. Fung, A. P. Nademanee, S. Bhatia, S. J. Forman, A. Sureda, and E. Conde
Is There an Association Between Total-Body Irradiation and Secondary Acute Myelogenous Leukemia/Myelodysplastic Syndrome in Patients With Relapsed/Refractory Hodgkin's Disease Treated With Autologous Stem-Cell Transplantation?
J. Clin. Oncol.,
August 1, 2001;
19(15):
3585 - 3588.
[Full Text]
|
|
|
|
|
|
|
D. M. Lillington, I. N.M. Micallef, E. Carpenter, M. J. Neat, J. A.L. Amess, J. Matthews, N. J. Foot, B. D. Young, T. A. Lister, and A. Z.S. Rohatiner
Detection of Chromosome Abnormalities Pre-High-Dose Treatment in Patients Developing Therapy-Related Myelodysplasia and Secondary Acute Myelogenous Leukemia After Treatment for Non-Hodgkin's Lymphoma
J. Clin. Oncol.,
May 1, 2001;
19(9):
2472 - 2481.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press, J. F. Eary, T. Gooley, A. K. Gopal, S. Liu, J. G. Rajendran, D. G. Maloney, S. Petersdorf, S. A. Bush, L. D. Durack, et al.
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas
Blood,
November 1, 2000;
96(9):
2934 - 2942.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al.
2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines
J. Clin. Oncol.,
October 20, 2000;
18(20):
3558 - 3585.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mounier, C. Gisselbrecht, J. W. Friedberg, D. Neuberg, and A. S. Freedman
Myelodysplasia After Autotransplantation
J. Clin. Oncol.,
October 19, 2000;
18(19):
3446 - 3447.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Pedersen-Bjergaard, M. K. Andersen, and D. H. Christiansen
Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation
Blood,
June 1, 2000;
95(11):
3273 - 3279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
